Quantcast

Latest Gram positive bacteria Stories

2014-08-19 08:29:22

-- Two of Company's Anti-Infective Programs to be Presented at Highly Regarded Scientific Conference: Pertussis and C. difficile -- ROCKVILLE, Md., Aug. 19, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its novel C. difficile development program will be highlighted at the 54(th) Interscience...

2014-08-06 12:29:16

St. Jude Children's Research Hospital discovery lays the groundwork for a new class of antibiotics to fight multi-drug resistant Staphylococcus aureus and related bacteria that cause serious infections. MEMPHIS, Tenn., Aug. 6, 2014 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital scientists have discovered an enzyme that regulates production of the toxins that contribute to potentially life-threatening Staphylococcus aureus infections. The study recently appeared in...

2014-08-05 08:32:23

-- Executed Agreement with Evonik for Formulation Development, Analytical Services andClinical Drug Manufacturing -- ROCKVILLE, Md., Aug. 5, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today announced that, with a new multi-service agreement in place, the Company is on track to initiate Phase Ia and Ib clinical trials of...

2014-07-29 12:36:03

ROCKVILLE, Md., July 29, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that in view of the unusual market activity in the Company's stock, the NYSE MKT (the "Exchange") has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity....

2014-07-16 08:29:22

SER-109 demonstrated remarkably high clinical cure rate and excellent safety profile CAMBRIDGE, Mass., July 16, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has completed enrollment for its single-arm, open-label clinical trial of SER-109, its first-in-field, oral microbiome therapeutic designed for the treatment of recurrent Clostridium difficile Infection...

2014-07-07 16:23:01

LONDON, July 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:MarketVIEW: Clostridium difficile vaccines http://www.reportbuyer.com/pharma_healthcare/therapeutic/marketview_clostridium_difficile_vaccines.htmlClostridium difficile (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDI). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients...

2014-07-07 12:28:38

Company's Breakthrough Innovation to Enable First Therapeutics for Microbiome-based Diseases CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pharmaceutical composition patent application that covers its lead product candidate, SER-109, which is currently...

2014-06-30 08:29:30

-- Company Expects to Initiate C. difficile Clinical Trials in 2014 -- ROCKVILLE, Md., June 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating...

2014-06-25 08:31:00

STOCKHOLM and CHESTERBROOK, Pa., June 25, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. The filing is based on positive safety and efficacy outcome data from two double-blind placebo-controlled studies, IMPRESS I and II (The...

Sharing A Common Microbiological Connection To Our Mobile Phones
2014-06-24 13:12:03

Gerard LeBlond for redorbit.com - Your Universe Online We might be more connected to our mobile phones than we think. According to recent research, such phones reflect a significant microbiological connection with their owners. The study focused on the collection of microorganisms on the items worn or carried by a person regularly. In a Robert Wood Johnson Foundation workshop in Princeton, New Jersey, researchers from the University of Oregon sequenced microbes from the dominant-hand...


Latest Gram positive bacteria Reference Libraries

0_acc42e71b0d88e5b1f3520ddbf139579
2011-04-28 14:45:47

Streptococcus salivarius is a species of spherical, Gram-positive bacteria which colonize the mouth and upper respiratory tract of humans a few hours after birth, making further exposure to the bacteria harmless. The bacterium is an opportunistic pathogen which rarely makes its way into the bloodstream where it is associated with septicemia cases in people with neutropenia. It has different characteristics when exposed to different environmental nutrients. In the lab a SYTA plate is used...

0_1b337eb3ae50456f130e22153cc80436
2011-04-28 14:40:22

Streptococcus pyogenes is a spherical, Gram-positive bacterium is the cause of Group A streptococcal infections. It displays streptococcal group A antigen on its cell wall. When it is cultured on blood agar plates it produces large zones of beta-hemolysis. They are catalase-negative and in ideal conditions it has an incubation period of about 1-3 days. It is an infrequent part of the skin flora. It is the cause of many important human diseases, ranging from mild superficial skin infections...

0_9fb0173be70876d98667eddc1e274866
2011-04-28 14:27:08

Streptococcus pneumoniae, or pneumococcus, is Gram-positive, alpha-hemolytic, bile-soluble aerotolerant, anaerobic member of the genus Streptococcus. It was recognized as a major cause of pneumonia in the late 19th century and is thus the subject of many humoral immunity studies. It causes many other types of pneumococcal infections other than pneumonia including acute sinusitis, otitis media, meningitis, bacteremia, sepsis, septic arthritis, peritonitis, cellulites, and brain abscess. It...

0_097d9a33e1035f1ca4b33243c5beaafa
2011-04-26 23:26:27

Streptococcus oralis is a Gram positive bacterium that grows characteristically in chains. On a Wilkins-Chalgren agar plate it will form slam white colonies. It is classified as a member of the streptococcus mitis group and is found in high numbers in the oral cavity. S. oralis produce neuraminidase and an IgA protease and cannot bind α-amylase.

0_b8b1f3bc239d54bf277f330c7dafdbb1
2011-04-26 23:21:38

Streptococcus mutans is a Gram-positive cocci, Facultative anaerobic bacterium commonly found in the human oral cavity and is a significant contributor to tooth decay. J Kilian Clarke first described the microbe in 1924. The first colonizers of the tooth surface are mainly Neisseria spp. and streptococci, including S. mutans. The pioneer species changes the local environmental conditions through growth and metabolism thus allowing more fastidious organisms to further colonize after them,...

More Articles (14 articles) »
Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related